Welcome to our dedicated page for Schrodinger SEC filings (Ticker: SDGR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Schrödinger, Inc. filings document an operating company with Software and Drug Discovery segments, including reported financial results, software revenue metrics, and disclosures about its computational platform for molecular discovery. Form 8-K reports furnish results of operations and material events, while other filings address clinical or regulatory disclosures and capital-structure matters.
Proxy and governance filings cover director elections, executive compensation, equity awards and shareholder voting matters. The record also includes disclosures about officer appointments, separation arrangements, compensatory matters, and voting rights for common stock and limited common stock, tying governance and ownership topics to the company's public-company structure.
Schrodinger, Inc. executive Robert Lorne Abel reported equity awards that increase his direct holdings. He received a stock option covering 34,250 shares, granted at an exercise price of $0.00 per share, scheduled to vest 25% on March 2, 2027 and monthly through March 2, 2030, subject to continued service.
He also acquired 17,130 restricted stock units (RSUs) that vest in four equal installments on March 9 of 2027, 2028, 2029 and 2030, and 20,682 performance-based RSUs tied to previously granted awards for which performance achievement was certified on March 2, 2026. These PRSUs are scheduled to vest upon the filing of the company’s Form 10-K for the year ended December 31, 2026, subject to continued service. Following these awards, his direct holdings include an aggregate of 52,949 unvested RSUs.
Schrödinger, Inc. uses a physics-based computational platform to speed discovery of new drugs and materials. In 2025 it generated total revenue of $255.9 million and recorded a net loss of $103.3 million, reflecting continued investment in R&D and platform growth.
Software remains the core business, with software revenue of $199.5 million, up 11% year over year, and annual contract value of $198.5 million. All top 20 global pharma companies by 2024 revenue licensed its tools, underscoring broad industry adoption.
The company deepened partnerships, including a major collaboration with Novartis that brought a $150.0 million upfront payment and up to $2.272 billion in potential milestones across initial programs. Additional collaborations with BMS, Lilly and Otsuka add future milestone and royalty potential.
Schrödinger is advancing proprietary drug candidates such as MALT1 inhibitor SGR‑1505 and Wee1/Myt1 inhibitor SGR‑3515 in Phase 1 trials, while it discontinued CDC7 inhibitor SGR‑2921 after safety concerns. Management plans to seek partners for later-stage development while focusing internally on early discovery and its growing software franchise.
Schrödinger, Inc. reported strong 2025 growth while still operating at a loss. Full-year revenue reached $255.9 million, up 23.3%, driven by $199.5 million of software revenue (up 10.6%) and drug discovery revenue of $56.4 million, more than double the prior year. Net loss narrowed to $103.3 million from $187.1 million, and year-end cash, cash equivalents, restricted cash and marketable securities totaled $402.3 million.
In the fourth quarter, revenue was $87.2 million and the company generated $32.5 million of net income versus a loss a year earlier, helped by $50.1 million of other income. Schrödinger is accelerating a shift from upfront on‑premise licenses to hosted, ratable software contracts, which it expects will pressure reported software revenue in the short to medium term but leave ACV and cash flow unchanged.
For 2026, management expects software ACV of $218–$228 million (10–15% growth) and drug discovery revenue of $55–$65 million, with operating expenses below 2025. The company is targeting positive adjusted EBITDA by the end of 2028 as hosted software becomes the dominant model and software gross margins return to the high‑70% range.
Schrodinger, Inc. received an updated ownership report from Rubric Capital Management and David Rosen. They report beneficial ownership of 4,171,498 shares of Schrodinger common stock, representing 6.47% of the company’s outstanding shares.
The shares are held through Rubric-managed funds, including Rubric Capital Master Fund LP, with Rubric and Rosen sharing voting and dispositive power over the reported stake. The percentage ownership is calculated using 64,500,510 Schrodinger shares outstanding as of October 29, 2025, as disclosed in the company’s recent quarterly report. The filers certify that the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Schrodinger.
Schrodinger, Inc. executive Yvonne Tran, EVP, CLO & CPO, sold 776 shares of common stock on 02/10/2026 at a weighted average price of $13.7956. The sale was executed under a durable Rule 10b5-1 automatic instruction to cover withholding taxes from vesting restricted stock units and was not a discretionary trade. Following this transaction, Tran beneficially owned 22,859 shares, including 14,398 unvested RSUs.
Schrodinger, Inc. executive Kenneth Patrick Lorton reported a small automatic sale of common stock tied to tax withholding. On 02/10/2026, he sold 925 shares of Schrodinger common stock in an open-market transaction at a weighted average price of $13.7338 per share under a pre-established Rule 10b5-1 plan. The sale was executed by a broker to cover withholding taxes arising from the vesting of restricted stock units and is described as non-discretionary. After this transaction, Lorton directly beneficially owned 52,651 shares of common stock, including 14,543 unvested RSUs.
Schrodinger, Inc.’s Chief Accounting Officer Jenny Herman reported an open-market sale of common stock. On February 10, 2026, she sold 752 shares at a weighted average price of $13.7904 under a pre-established Rule 10b5-1 trading plan to cover withholding taxes from RSU vesting.
After this transaction, she directly beneficially owns 26,597 shares of Schrodinger common stock, which includes 17,285 unvested RSUs. The filing notes the sale was not a discretionary trade and that the shares were sold in multiple transactions between $13.71 and $13.85.
Abel Robert Lorne reported open-market sale transactions in a Form 4 filing for SDGR. The filing lists transactions totaling 1,230 shares at a weighted average price of $13.51 per share. Following the reported transactions, holdings were 19,385 shares.